Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $62.25.

Several equities analysts have recently weighed in on CLDX shares. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a "buy" rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wolfe Research lowered shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th.

Celldex Therapeutics Stock Down 1.0 %

NASDAQ CLDX traded down $0.26 during trading hours on Friday, hitting $25.39. 719,618 shares of the company were exchanged, compared to its average volume of 889,613. Celldex Therapeutics has a 52 week low of $22.93 and a 52 week high of $53.18. The stock has a 50-day moving average price of $26.38 and a 200 day moving average price of $33.03. The stock has a market cap of $1.68 billion, a PE ratio of -9.88 and a beta of 1.57.

Insiders Place Their Bets

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm's stock in a transaction on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.80% of the company's stock.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky lifted its position in shares of Celldex Therapeutics by 5.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company's stock worth $1,449,000 after purchasing an additional 2,070 shares during the period. Geode Capital Management LLC lifted its holdings in Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock worth $52,372,000 after buying an additional 6,557 shares during the period. Barclays PLC boosted its position in Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after acquiring an additional 76,207 shares in the last quarter. Y Intercept Hong Kong Ltd increased its holdings in shares of Celldex Therapeutics by 11.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company's stock valued at $1,038,000 after acquiring an additional 3,146 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $1,561,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.